Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC
Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing... Read More
Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing... Read More
Among the many approaches and treatment combinations available for men with high-risk localized prostate cancer, the optimal strategy remains to... Read More
The American Society of Clinical Oncology (ASCO) has released new guidelines to address abiraterone or docetaxel with androgen-deprivation therapy (ADT)... Read More
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the... Read More
Focal therapy for primary localized prostate cancer should remain investigational pending further study, according to a 2018 European Association of... Read More
Two-year post-radiotherapy biopsies do not predict survival for most men with prostate cancer, according to results from the RT01 trial.... Read More